一分钟看懂
这是一项关于实体瘤的I 期研究，登记的药物或干预包括DXP-106，当前状态为招募中。登记地点显示中国哈尔滨、上海、太原、杭州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
DXP-106 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Harbin Medical University Cancer Hospital · 哈尔滨
- Zhongshan Hospital, Fudan University · 上海
- The First Hospital of Shanxi Medical University · 太原
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University · 杭州
公开的入选条件
- Inclusion criteria:
- * Participants who fully understand the trial objectives, nature, procedures, and potential adverse reactions, and who voluntarily agree to participate in the study and provide signed informed consent.
- * Patients aged 18 to 80 years (inclusive, based on the date of signing the informed consent form), both male and female.
- * Measurable disease as assessed by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST criteria within 4 weeks prior to screening.
- * Study Population
- Part 1: Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are ineligible for surgery or curative radiotherapy and have experienced disease progression after standard treatment or are intolerant to such ther
- Part 2: If the participant received adjuvant/neoadjuvant therapy before or after completing prior curative treatment, and the participant's disease has recurred, the interval between the end of adjuvant/neoadjuvant therapy and the first dose in this study must
- LC patients: Patients with locally advanced/metastatic lung cancer confirmed by histology or cytology, who relapsed after first-line treatment and must meet the criteria for receiving platinum-based chemotherapy as first-line or second-line standard treatment;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07532018；登记信息更新于 2026-09-15。